{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:56:16Z","timestamp":1790488576906,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.4158\/ep12086.ra","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T21:05:28Z","timestamp":1342040728000},"page":"954-964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Thyroid Hormone Analogues for the Treatment of Metabolic Disorders: New Potential for Unmet Clinical Needs?"],"prefix":"10.1016","volume":"18","author":[{"given":"Timothy J.","family":"Shoemaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyoshi","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary N.","family":"Mariash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmella","family":"Evans-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP12086.RA_bb0010","unstructured":"Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. www.cdc.gov\/diabetes\/pubs\/pdf\/ndfs_2011.pdf"},{"key":"10.4158\/EP12086.RA_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2009.2014","article-title":"Prevalence and trends in obesity among US adults, 1999-2008","volume":"303","author":"Flegal","year":"2010","journal-title":"JAMA"},{"key":"10.4158\/EP12086.RA_bb0020","unstructured":"American Diabetes Association. 2011 National Diabetes Fact Sheet. http:\/\/www.diabetes.org\/diabetes-basics\/diabetes-statistics\/?loc=DropDownDB-stats"},{"key":"10.4158\/EP12086.RA_bb0025","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.2337\/dc06-1136","article-title":"Impact of recent increase in incidence on future diabetes burden: U. S., 2005-2050","volume":"29","author":"Narayan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12086.RA_bb0030","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1001\/jama.290.14.1884","article-title":"Lifetime risk for diabetes mellitus in the United States","volume":"290","author":"Narayan","year":"2003","journal-title":"JAMA"},{"key":"10.4158\/EP12086.RA_bb0035","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","article-title":"Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"10.4158\/EP12086.RA_bb0040","unstructured":"American Heart Association. Conditions associated with Coronary Heart Disease. http:\/\/www.heart.org\/HEARTORG\/Conditions\/Conditions_UCM_001087_SubHomePage.jsp"},{"key":"10.4158\/EP12086.RA_bb0045","first-page":"128","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"82","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.4158\/EP12086.RA_bb0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP12086.RA_bb0055","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1185\/03007995.2010.522490","article-title":"Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2","volume":"26","author":"Jukema","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP12086.RA_bb0060","unstructured":"Atar D, Ong S, Lansberg PJ. Expanding the evidence base: comparing randomized controlled trials and observational studies of statins. Am J Ther. 2012 [Epub ahead of print]."},{"issue":"suppl 1","key":"10.4158\/EP12086.RA_bb0065","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc11-S011","article-title":"Standards of medical care in diabetes\u20142011.","volume":"34","author":"American Diabetes Association","year":"2011","journal-title":"Diabetes Care."},{"key":"10.4158\/EP12086.RA_bb0070","first-page":"304","article-title":"Prevalence of achievement of A1c, blood pressure, and cholesterol (ABC) goal in veterans with diabetes","volume":"17","author":"Vouri","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"10.4158\/EP12086.RA_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2006.10.003","article-title":"Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study","volume":"22","author":"Bertoni","year":"2008","journal-title":"J Diabetes Complications"},{"key":"10.4158\/EP12086.RA_bb0080","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1001\/jama.298.17.2028","article-title":"Cause-specific excess deaths associated with underweight, overweight, and obesity","volume":"298","author":"Flegal","year":"2007","journal-title":"JAMA"},{"key":"10.4158\/EP12086.RA_bb0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/clpt.2011.82","article-title":"New drug targets for the treatment of obesity","volume":"90","author":"Powell","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.4158\/EP12086.RA_bb0090","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12086.RA_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/er.2009-0007","article-title":"Molecular aspects of thyroid hormone actions","volume":"31","author":"Cheng","year":"2010","journal-title":"Endocr Rev"},{"key":"10.4158\/EP12086.RA_bb0100","series-title":"Basic and Clinical Endocrinology.","first-page":"215","article-title":"The Thyroid Gland","author":"Greenspan","year":"2004"},{"key":"10.4158\/EP12086.RA_bb0105","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0026-0495(84)90203-8","article-title":"Mechanisms governing the relative proportions of thyroxine and 3,5,3'-triiodothyronine in thyroid secretion","volume":"33","author":"Laurberg","year":"1984","journal-title":"Metabolism"},{"key":"10.4158\/EP12086.RA_bb0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1172\/JCI6397","article-title":"Divergent roles for thyroid hormone receptor beta isoforms in the endocrine axis and auditory system","volume":"104","author":"Abel","year":"1999","journal-title":"J Clin Invest"},{"key":"10.4158\/EP12086.RA_bb0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/105072502760143791","article-title":"Mechanism of thyroid hormone action","volume":"12","author":"Harvey","year":"2002","journal-title":"Thyroid"},{"key":"10.4158\/EP12086.RA_bb0120","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1210\/me.2002-0296","article-title":"A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone","volume":"17","author":"O'Shea","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.4158\/EP12086.RA_bb0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-132-4-200002150-00004","article-title":"Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study","volume":"132","author":"Hak","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP12086.RA_bb0130","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJM193012252032601","article-title":"Blood cholesterol values in hyperthyroidism and hypothyroidism\u2014their significance","volume":"203","author":"Mason","year":"1930","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12086.RA_bb0135","first-page":"120","article-title":"Long-term effect of dried thyroid on serum-lipoprotein and serum-cholesterol levels","volume":"272","author":"Galioni","year":"1957","journal-title":"Lancet"},{"key":"10.4158\/EP12086.RA_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.CIR.2.2.161","article-title":"Blood lipids and human atherosclerosis","volume":"2","author":"Gofman","year":"1950","journal-title":"Circulation"},{"key":"10.4158\/EP12086.RA_bb0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/jcem-15-1-73","article-title":"Effect of long-term administration of desiccated thyroid on serum lipoprotein and cholesterol levels","volume":"15","author":"Strisower","year":"1955","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12086.RA_bb0150","first-page":"218","article-title":"Effect of thyroid extract on serum lipoproteins and serum cholesterol","volume":"3","author":"Strisower","year":"1954","journal-title":"Metabolism"},{"key":"10.4158\/EP12086.RA_bb0155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jacl.2010.10.002","article-title":"Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006","volume":"4","author":"Robinson","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.4158\/EP12086.RA_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosissup.2004.08.027","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atheroscler Suppl"},{"key":"10.4158\/EP12086.RA_bb0165","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.amjcard.2004.09.034","article-title":"Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome","volume":"95","author":"Deedwania","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.4158\/EP12086.RA_bb0170","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1073\/pnas.0702759104","article-title":"Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index","volume":"104","author":"Erion","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP12086.RA_bb0175","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12086.RA_bb0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1253\/jcj.64.51","article-title":"Lipoprotein(a) is a potential coronary risk factor","volume":"64","author":"Fujino","year":"2000","journal-title":"Jpn Circ J"},{"key":"10.4158\/EP12086.RA_bb0185","first-page":"5958","article-title":"Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport","volume":"16","author":"Pedrelli","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.4158\/EP12086.RA_bb0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1677\/jme.0.0220103","article-title":"Hormonal regulation of apolipoprotein AI","volume":"22","author":"Hargrove","year":"1999","journal-title":"J Mol Endocrinol"},{"key":"10.4158\/EP12086.RA_bb0195","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1073\/pnas.0504379102","article-title":"Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice","volume":"102","author":"Johansson","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP12086.RA_bb0200","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1210\/endo.141.9.7681","article-title":"The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity","volume":"141","author":"Trost","year":"2000","journal-title":"Endocrinology"},{"key":"10.4158\/EP12086.RA_bb0205","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1210\/en.2003-0973","article-title":"Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine","volume":"145","author":"Grover","year":"2004","journal-title":"Endocrinology"},{"key":"10.4158\/EP12086.RA_bb0210","unstructured":"Lin VH, Klepp HM, Hanley RM. Sobetirome is a TR- and liver selective thyromimetic that can effect substantial LDL-C lowering without significant changes in heart rate or the thyroid axis in euthyroid men. Presented at the 90th Annual Meeting of The Endocrine Society, June 15-18, 2008; San Francisco, California."},{"key":"10.4158\/EP12086.RA_bb0215","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1161\/CIRCULATIONAHA.108.834424","article-title":"DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study","volume":"119","author":"Goldman","year":"2009","journal-title":"Circulation"},{"key":"10.4158\/EP12086.RA_bb0220","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP12086.RA_bb0225","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jsbmb.2008.06.010","article-title":"Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB141","volume":"111","author":"Bryzgalova","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.4158\/EP12086.RA_bb0230","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1073\/pnas.1633737100","article-title":"Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability","volume":"100","author":"Grover","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP12086.RA_bb0235","doi-asserted-by":"crossref","first-page":"e8722","DOI":"10.1371\/journal.pone.0008722","article-title":"The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice","volume":"5","author":"Tancevski","year":"2010","journal-title":"PLoS One"},{"key":"10.4158\/EP12086.RA_bb0240","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1194\/jlr.M800553-JLR200","article-title":"The thyromimetic T-0681 protects from atherosclerosis","volume":"50","author":"Tancevski","year":"2009","journal-title":"J Lipid Res"},{"key":"10.4158\/EP12086.RA_bb0245","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1210\/jc.2009-1209","article-title":"Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study","volume":"95","author":"Ladenson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12086.RA_bb0250","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/13543771003662636","article-title":"Diiodothyropropionic acid: WO2008106213","volume":"20","author":"Raval","year":"2010","journal-title":"Expert Opin Ther Pat"},{"key":"10.4158\/EP12086.RA_bb0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1677\/joe.1.07066","article-title":"Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats","volume":"193","author":"Villicev","year":"2007","journal-title":"J Endocrinol"},{"key":"10.4158\/EP12086.RA_bb0260","first-page":"348","article-title":"The syndromes of resistance to thyroid hormone","volume":"14","author":"Refetoff","year":"1993","journal-title":"Endocr Rev"},{"key":"10.4158\/EP12086.RA_bb0265","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/emboj\/17.2.455","article-title":"Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1","volume":"17","author":"Wikstr\u00f6m","year":"1998","journal-title":"EMBO J"},{"key":"10.4158\/EP12086.RA_bb0270","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/j.1460-2075.1996.tb00664.x","article-title":"Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function","volume":"15","author":"Forrest","year":"1996","journal-title":"EMBO J"},{"key":"10.4158\/EP12086.RA_bb0275","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1210\/me.2007-0157","article-title":"Thyroid status during skeletal development determines adult bone structure and mineralization","volume":"21","author":"Bassett","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.4158\/EP12086.RA_bb0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1677\/JME-08-0142","article-title":"The skeletal phenotypes of TRalpha and TRbeta mutant mice","volume":"42","author":"Bassett","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"10.4158\/EP12086.RA_bb0285","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM198803103181003","article-title":"Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature","volume":"318","author":"Rivkees","year":"1988","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12086.RA_bb0290","first-page":"1277","article-title":"The aftermath of childhood hyperthyroidism","volume":"14","author":"Segni","year":"2001","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.4158\/EP12086.RA_bb0295","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1472-6823-11-15","article-title":"Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men","volume":"11","author":"El Hadidy","year":"2011","journal-title":"BMC Endocr Disord"},{"key":"10.4158\/EP12086.RA_bb0300","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jama.1972.03200070084015","article-title":"The coronary drug project: findings leading to further modifications of its protocol with respect to dextrothyroxine.","volume":"220","author":"Coronary Drug Project Research Group","year":"1972","journal-title":"JAMA."},{"key":"10.4158\/EP12086.RA_bb0305","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI111667","article-title":"Stereospecific transport of triiodothyronine from plasma to cytosol and from cytosol to nucleus in rat liver, kidney, brain, and heart","volume":"75","author":"Oppenheimer","year":"1985","journal-title":"J Clin Invest"},{"key":"10.4158\/EP12086.RA_bb0310","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1210\/endo-113-4-1236","article-title":"Distribution and metabolism of L- and D-triiodothyronine (T3) in the rat: preferential accumulation of L-T3 by hepatic and cardiac nuclei as a probable explanation of the differential biological potency of T3 enantiomers","volume":"113","author":"Schwartz","year":"1983","journal-title":"Endocrinology"},{"key":"10.4158\/EP12086.RA_bb0315","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/clpt.1984.257","article-title":"L-thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect","volume":"36","author":"Young","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"10.4158\/EP12086.RA_bb0320","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1681\/ASN.V9190","article-title":"D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients","volume":"9","author":"Bommer","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.4158\/EP12086.RA_bb0325","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/thy.2007.0248","article-title":"Metabolic effects of thyroid hormone derivatives","volume":"18","author":"Moreno","year":"2008","journal-title":"Thyroid"},{"key":"10.4158\/EP12086.RA_bb0330","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.steroids.2008.11.014","article-title":"Characterization of ligands for thyroid receptor subtypes and their interactions with co-regulators","volume":"74","author":"Koury","year":"2009","journal-title":"Steroids"},{"key":"10.4158\/EP12086.RA_bb0335","first-page":"2153","article-title":"Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine","volume":"82","author":"Sherman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12086.RA_bb0340","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1172\/JCI103273","article-title":"The hemodynamics of thyrotoxicosis in man with special reference to coronary blood flow and myocardial oxygen metabolism","volume":"35","author":"Rowe","year":"1956","journal-title":"J Clin Invest"},{"key":"10.4158\/EP12086.RA_bb0345","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0002-8703(58)90164-9","article-title":"The circulation in hyperthyroidism: a cardiac catheterization study before and after treatment","volume":"56","author":"Humerfelt","year":"1958","journal-title":"Am Heart J"},{"key":"10.4158\/EP12086.RA_bb0350","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI103906","article-title":"A correlation of clinical and hemodynamic studies in patients with hyperthyroidism with and without congestive heart failure","volume":"38","author":"Graettinger","year":"1959","journal-title":"J Clin Invest"},{"key":"10.4158\/EP12086.RA_bb0355","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-3565(25)10319-4","article-title":"Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity","volume":"263","author":"Pennock","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.4158\/EP12086.RA_bb0360","unstructured":"U. S. National Institutes of Health, Clinical Trials.gov. http:\/\/clinicaltrials.gov\/ct2\/search"},{"key":"10.4158\/EP12086.RA_bb0365","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/378690a0","article-title":"A structural role for hormone in the thyroid hormone receptor","volume":"378","author":"Wagner","year":"1995","journal-title":"Nature"},{"key":"10.4158\/EP12086.RA_bb0370","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1074-5521(98)90168-5","article-title":"A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor","volume":"5","author":"Chiellini","year":"1998","journal-title":"Chem Biol"},{"key":"10.4158\/EP12086.RA_bb0375","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1055\/s-0031-1291177","article-title":"Cardiac specific effects of thyroid hormone analogues","volume":"43","author":"Danzi","year":"2011","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP12086.RA_bb0380","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1016\/j.bmc.2012.03.056","article-title":"Discovery of novel indane derivatives as liver-selective thyroid hormone receptor \u03b2 (TR\u03b2) agonists for the treatment of dyslipidemia","volume":"20","author":"Shiohara","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.4158\/EP12086.RA_bb0385","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1021\/ja031818y","article-title":"Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver","volume":"126","author":"Erion","year":"2004","journal-title":"J Am Chem Soc"},{"key":"10.4158\/EP12086.RA_bb0390","doi-asserted-by":"crossref","first-page":"20717","DOI":"10.1073\/pnas.0911024106","article-title":"Gaining ligand selectivity in thyroid hormone receptors via entropy","volume":"106","author":"Martinez","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP12086.RA_bb0395","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd2830","article-title":"Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes","volume":"8","author":"Baxter","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.4158\/EP12086.RA_bb0400","unstructured":"QUATRx. Clinical Portfolio: Developing new therapies for endocrine, metabolic, and cardiovascular diseases. http:\/\/www.quatrx.com\/clinical\/index.htm"},{"key":"10.4158\/EP12086.RA_bb0405","unstructured":"FierceBiotech. Metabasis therapeutics announces the publication of pre-clinical findings on MB07811, its product candidate. http:\/\/www.fiercebiotech.com\/press-releases\/metabasis-therapeutics-announces-publication-pre-clinical-findings-mb07811-its-produc"},{"key":"10.4158\/EP12086.RA_bb0410","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1750-3639.2009.00038.x","article-title":"Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys","volume":"156","author":"Ito","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.4158\/EP12086.RA_bb0415","unstructured":"Ligand Pharmaceuticals. Ligand Pipeline. http:\/\/www.ligand.com\/pipeline"},{"key":"10.4158\/EP12086.RA_bb0420","unstructured":"Karo Bio. Karo Bio terminates the eprotirome program. http:\/\/www.karobio.com"},{"key":"10.4158\/EP12086.RA_bb0425","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/thy.1995.5.481","article-title":"Thyroid hormone control of thermogenesis and energy balance","volume":"5","author":"Silva","year":"1995","journal-title":"Thyroid"},{"key":"10.4158\/EP12086.RA_bb0430","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MED.0b013e32833d6d46","article-title":"New insights into regulation of lipid metabolism by thyroid hormone","volume":"17","author":"Zhu","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.4158\/EP12086.RA_bb0435","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1172\/JCI200112584","article-title":"Thyroid hormone\u2014sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform\u2014specific","volume":"108","author":"Ribeiro","year":"2001","journal-title":"J Clin Invest"},{"key":"10.4158\/EP12086.RA_bb0440","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0028-1093403","article-title":"Specific weight loss in hyperthyroidism","volume":"10","author":"Bratusch-Marrain","year":"1978","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP12086.RA_bb0445","first-page":"71","article-title":"Influence of experimental hyperthyroidism on skeletal muscle metabolism in the rat","volume":"85","author":"van Hardeveld","year":"1977","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.4158\/EP12086.RA_bb0450","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2011-1329","article-title":"Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine","volume":"96","author":"Celi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP12086.RA_bb0455","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1210\/en.2004-1544","article-title":"Temperature homeostasis in transgenic mice lacking thyroid hormone receptor-alpha gene products","volume":"146","author":"Marrif","year":"2005","journal-title":"Endocrinology"},{"key":"10.4158\/EP12086.RA_bb0460","doi-asserted-by":"crossref","first-page":"E1135","DOI":"10.1152\/ajpendo.00506.2002","article-title":"Spared bone mass in rats treated with thyroid hormone receptor TR beta-selective compound GC-1","volume":"285","author":"Freitas","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.4158\/EP12086.RA_bb0465","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1378\/chest.115.3.836","article-title":"Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation","volume":"115","author":"Anker","year":"1999","journal-title":"Chest"},{"key":"10.4158\/EP12086.RA_bb0470","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1677\/JOE-08-0539","article-title":"A TRbeta-selective agonist confers resistance to diet-induced obesity","volume":"203","author":"Amorim","year":"2009","journal-title":"J Endocrinol"},{"key":"10.4158\/EP12086.RA_bb0475","doi-asserted-by":"crossref","first-page":"E1380","DOI":"10.1152\/ajpendo.90700.2008","article-title":"PPARalpha activation and increased dietary lipid oppose thyroid hormone signaling and rescue impaired glucose-stimulated insulin secretion in hyperthyroidism","volume":"295","author":"Holness","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.4158\/EP12086.RA_bb0480","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1042\/bj2470801","article-title":"Continued glucose output after re-feeding contributes to glucose intolerance in hyperthyroidism","volume":"247","author":"Holness","year":"1987","journal-title":"Biochem J"},{"key":"10.4158\/EP12086.RA_bb0485","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1210\/er.2009-0046","article-title":"Insulin action in hyperthyroidism: a focus on muscle and adipose tissue","volume":"31","author":"Mitrou","year":"2010","journal-title":"Endocr Rev"},{"key":"10.4158\/EP12086.RA_bb0490","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1432-1033.1969.tb00672.x","article-title":"The role of thyroid function in the metabolism of perfused rat liver with particular reference to gluconeogenesis","volume":"10","author":"Menahan","year":"1969","journal-title":"Eur J Biochem"},{"key":"10.4158\/EP12086.RA_bb0495","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1432-1033.1970.tb00925.x","article-title":"Fluctuation of hepatic enzymes important in glucose metabolism in relation to thyroid function","volume":"13","author":"B\u00f6ttger","year":"1970","journal-title":"Eur J Biochem"},{"key":"10.4158\/EP12086.RA_bb0500","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF01725187","article-title":"Thyroid hormone action on intermediary metabolism: Part I; respiration, thermogenesis and carbohydrate metabolism","volume":"62","author":"M\u00fcller","year":"1984","journal-title":"Klin Wochenschr"},{"key":"10.4158\/EP12086.RA_bb0505","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF01219514","article-title":"The inhibition of insulin secretion from the perfused rat pancreas after thyroxine treatment","volume":"12","author":"Lenzen","year":"1976","journal-title":"Diabetologia"},{"key":"10.4158\/EP12086.RA_bb0510","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0026-0495(78)90126-9","article-title":"Dose-response studies on the inhibitory effect of thyroid hormones on insulin secretion in the rat","volume":"27","author":"Lenzen","year":"1978","journal-title":"Metabolism"},{"key":"10.4158\/EP12086.RA_bb0515","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0028-1093418","article-title":"Carbohydrate metabolism in thyrotoxicosis: studies on insulin secretion before and after remission from the hyperthyroid state","volume":"10","author":"Wajchenberg","year":"1978","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP12086.RA_bb0520","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4161\/isl.2.2.11170","article-title":"The thyroid hormone T3 improves function and survival of rat pancreatic islets during in vitro culture","volume":"2","author":"Verga Falzacappa","year":"2010","journal-title":"Islets"},{"key":"10.4158\/EP12086.RA_bb0525","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jcb.22045","article-title":"The TRbeta1 is essential in mediating T3 action on Akt pathway in human pancreatic insulinoma cells","volume":"106","author":"Verga Falzacappa","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.4158\/EP12086.RA_bb0530","doi-asserted-by":"crossref","first-page":"e19839","DOI":"10.1371\/journal.pone.0019839","article-title":"Thyroid hormone T3 counteracts STZ induced diabetes in mouse","volume":"6","author":"Verga Falzacappa","year":"2011","journal-title":"PLoS One"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20430186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20430186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/R572115521589372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:55:56Z","timestamp":1761515756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20430186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1530891X20430186"],"URL":"https:\/\/doi.org\/10.4158\/ep12086.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid Hormone Analogues for the Treatment of Metabolic Disorders: New Potential for Unmet Clinical Needs?","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP12086.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}